Rhone-Poulenc Rorer Zagam
Executive Summary
Exclusive U.S. marketing and manufacturing rights acquired by Mylan. Zagam (sparfloxacin), which is licensed from Dainippon, will be promoted and detailed through Mylan's branded subsidiary Bertek Pharmaceuticals. Zagam sales for the year ending in June totaled $4.4 million, according to IMS Health